[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CERo Therapeutics Holdings, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100580206",false,"NCT06834282","CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","Phase 1\u002F1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)","CertainT-1","Inclusion Criteria:\n\n* Patients need to have a confirmed diagnosis of de novo or secondary AML, or myelodysplastic syndrome (MDS)\u002FAML with 10% to 19% blasts, per the International Consensus Classification 2022 or the WHO 2022 classification.\n* Absolute lymphocyte count \\>0.3 x 109\u002FL prior to apheresis.\n* Eastern cooperative oncology group (ECOG) performance status 0 to 1.\n\nExclusion Criteria:\n\n* Prior therapy with a permanently integrated, genetically modified cell product.\n* No measurable leukemia on the screening bone marrow evaluation prior to any bridging therapy.\n* Active autoimmune disease or history of autoimmune disease requiring treatment within the prior 2 years. Patients with history of autoimmune thyroiditis or type 1 diabetes well controlled on replacement regimen are eligible.\n* A known hypersensitivity or severe allergy to fludarabine, cyclophosphamide, or study drug components or diluents.\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the physician.\n* Primary immunodeficiency disorder.","ALL","18 Years","85 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a first in human, multi center, open label, phase 1\u002F1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed\u002Frefractory (R\u002FR), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.",[27,28,29],"AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[31],"Relapsed Acute Myeloid Leukemia","RECRUITING","2026-03-23",{"date":35,"type":36},"2026-03-27","ACTUAL",{"date":38,"type":36},"2025-04-07",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"CERo Therapeutics Holdings, Inc.","INDUSTRY",4,""]